Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03627936 · ClinicalTrials.gov registry record · Phase 1
A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT03627936 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 40 participants.
The verdict
NCT03627936, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the bioequivalence between lorcaserin XR tablets manufactured in Kawashima and lorcaserin XR tablets manufactured in Zofingen.
Interventions
- DRUG Lorcaserin manufactured at Zofingen
- DRUG Lorcaserin manufactured at Kawashima
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-08-07 |
| Est. Completion | 2018-09-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03627936
The ClinicalTrials.gov registry entry for NCT03627936 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lorcaserin manufactured at Zofingen is the first listed.
NCT03627936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03627936 about?
NCT03627936 is a clinical study titled "A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants". The purpose of this study is to demonstrate the bioequivalence between lorcaserin XR tablets manufactured in Kawashima and lorcaserin XR tablets manufactured in Zofingen.
What is the current status of trial NCT03627936?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2018-08-07. Estimated completion is 2018-09-02.
What interventions are being tested in trial NCT03627936?
The interventions under investigation include: Lorcaserin manufactured at Zofingen (DRUG), Lorcaserin manufactured at Kawashima (DRUG).
Who is sponsoring clinical trial NCT03627936?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.